Home / Going-concern warnings / Pelthos Therapeutics Inc.
Filed 2026-08-13 路 Form 10-Q 路 Accession 0001919246-26-000113 micro
Price before filing: $28.91 (2026-08-12 close, split/dividend-adjusted)
Market cap at flag: $102.5M (2026-08-13) 路 Latest: $71.3M (2026-10-16)
| Window | PTHS | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -24.1% | -1.5% | -22.6% | 2026-09-14 |
| 90 days | pending | pending | until 2026-11-11 | |
| 180 days | pending | pending | until 2027-02-09 | |
| 1 year | pending | pending | until 2027-08-13 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 4 insiders sold $104K (9 sales); 1 insider bought $1000K (2 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Francis Knuettel II CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40K | no | Form 4 |
| 2026-06-11 | Davis Todd C Director | Purchase | 35,445 | $27.80 | $986K | no | Form 4 |
| 2026-06-11 | Davis Todd C Director | Purchase | 503 | $28.73 | $14K | no | Form 4 |
| 2026-06-15 | Friedberg Ezra M Director | Sale | 224 | $27.12 | $6K | yes | Form 4 |
| 2026-06-15 | Friedberg Ezra M Director | Sale | 59 | $27.94 | $2K | yes | Form 4 |
| 2026-07-02 | Friedberg Ezra M Director | Sale | 534 | $26.03 | $14K | yes | Form 4 |
| 2026-07-02 | Friedberg Ezra M Director | Sale | 24 | $27.33 | $656 | yes | Form 4 |
| 2026-07-02 | Greenleaf Peter Director | Sale | 712 | $26.00 | $19K | yes | Form 4 |
| 2026-07-02 | Greenleaf Peter Director | Sale | 85 | $27.27 | $2K | yes | Form 4 |
| 2026-07-02 | Pauls Matthew Director | Sale | 692 | $26.00 | $18K | yes | Form 4 |
| 2026-07-02 | Pauls Matthew Director | Sale | 94 | $27.36 | $3K | yes | Form 4 |
| 2026-08-13: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-05-15 to 2026-09-12. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions."
Quoted from the filing. Source
Going-concern doubt disclosed, then alleviated: the company said conditions raised substantial doubt about its ability to continue as a going concern, but that its plans or new funding resolve that doubt for the next 12 months. A weaker warning than an unresolved going-concern doubt, but the company recently needed a rescue plan or fresh money to stay afloat.
Source: management disclosure in Form 10-Q (period 2026-06-30)
Status: doubt alleviated (the company says its plans or new funding resolve the substantial doubt it disclosed)
Why this score: substantial doubt disclosed, then alleviated by management's plans or new funding; quarterly (unaudited) disclosure; also within 90 days: Auditor change, Non-reliance / restatement
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.